Примери за използване на Physician should consider на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
In case of neutropenia, the physician should consider the use of growth factors.
If renal dysfunction develops during treatment with lisinopril(serum creatinine concentration exceeding 265 mol/L ora doubling from the pretreatment value), then the physician should consider withdrawal of lisinopril.
In case of neutropenia, the physician should consider the use of growth factors in patient management.
When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before orthree hours after sevelamer carbonate, or the physician should consider monitoring blood levels.
If a patient reports tinnitus or hearing loss during aminoglycoside therapy, the physician should consider referring them for audiological assessment.
When you assign other drugs the physician should consider not only individual characteristics of the patient, but also their interaction with the"L-thyroxin".
If a patient reports tinnitus or hearing loss during TOBI Podhaler therapy the physician should consider referring them for audiological assessment.
If severe toxicity occurs, the physician should consider delaying or discontinuing the therapy with the medicinal product until serious complications resolve.
Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow therapeutic window, the clinical effect and adverse events should be monitored, on initiation or doseadjustment of either Velphoro orthe concomitant medicinal product, or the physician should consider measuring blood levels.
In case of thrombotic complication, the physician should consider discontinuing rFVIIa or FVIII and interrupt Hemlibra prophylaxis as clinically indicated.
If patients have a continued decrease in left ventricular function, butremain asymptomatic, the physician should consider discontinuing therapy if no clinical benefit of Herceptin therapy has been seen.
In the case of an amyloid positiveinitial visual read and negative quantitation, the physician should consider whether the positive visual interpretation might be based on tracer retention in regions outside the ROIs that contribute to the cortical average standardised uptake value ratio(SUVR).
If patients have a continued decrease in left ventricular function, butremain asymptomatic, the physician should consider discontinuing therapy if no clinical benefit of Herceptin therapy has been seen.
If there is evidence of continued therapy-induced cough with TOBI Podhaler, the physician should consider whether an approved tobramycin nebuliser solution should be used as an alternative treatment.
Physicians should consider clinical monitoring for these patients.
In the event of overdose, treatment with talazoparib should be stopped, and physicians should consider gastric decontamination, follow general supportive measures and treat symptomatically.
If signs or symptoms occur physicians should consider discontinuing either one or both agents;
Physicians should consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive or behavioural signs or symptoms.
If decline in walking ability is observed, physicians should consider an interruption to treatment in order to reassess the benefits of Fampyra(see above).
Due to the sensitive nature of the topic, physicians should consider screening for ED in at-risk patients, as information may not be volunteered,” the authors write.
Physicians should consider discontinuing therapy if an adequate response has not been achieved or the patient fails to follow the requirement for scheduled liver test monitoring.
Physicians should consider hospitalisation for the first 10 days post infusion or at the first signs or symptoms of CRS and/or neurologic events.
Physicians should consider pre-treatment(e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab.
Physicians should consider delaying initiation of LEMTRADA administration in patients with active infection until the infection is fully controlled.
Physicians should consider the benefit/risk balance of the available treatment options(pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) before initiating treatment in previously untreated patients with non-small cell lung cancer whose tumours express PD-L1.
Physicians should consider the benefit/risk balance of the available treatment options(pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) before initiating treatment in patients with head and neck squamous cell carcinoma whose tumours express PD-L1(see section 5.1).
Since iron-based preparations are known to reduce the absorption of levothyroxine(thyroxine), physicians should consider monitoring suitable markers or clinical signs of efficacy if these medicinal products are concomitantly administered with Fexeric.
These infections are often related to a high total immunosuppressive burden and may lead to serious orfatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.
When administering medicinal products for which alterations in blood levels could have a clinically significant effect on safety or efficacy, physicians should consider monitoring serum levels or effects.